# Traditional Chinese medicine in diabetes management: a comprehensive review of mechanisms and therapeutic potential

**Authors:** Yuzhe Fan, Shengjie Gong, Xu Wang

PMC · DOI: 10.3389/fendo.2026.1709404 · Frontiers in Endocrinology · 2026-03-03

## TL;DR

This paper reviews how Traditional Chinese Medicine can help manage diabetes by targeting multiple pathways and improving outcomes.

## Contribution

The paper provides a comprehensive review of TCM's mechanisms and clinical applications in diabetes management.

## Key findings

- TCM modulates insulin secretion and improves glucose metabolism.
- Bioactive compounds in TCM regulate pathways like PI3K/Akt and Nrf2/HO-1.
- TCM shows potential in reducing complications like diabetic retinopathy and neuropathy.

## Abstract

Diabetes mellitus is a chronic metabolic disorder frequently associated with severe complications. Traditional Chinese Medicine (TCM) offers potential therapeutic benefits through multi-targeted mechanisms.

This study explores the pharmacological actions, clinical applications, and therapeutic potential of TCM herbs, extracts, and prescriptions in managing diabetes-related complications.

A comprehensive review of studies from multiple databases was conducted, focusing on experimental evidence, signaling pathways, and clinical trials evaluating TCM interventions for diabetes and its complications.

TCM demonstrates significant potential in modulating insulin secretion, improving glucose metabolism, and attenuating oxidative stress. Specific formulations and bioactive compounds regulate pathways including PI3K/Akt, Nrf2/HO-1, and VEGF, contributing to better glycemic control and reduced complications such as diabetic retinopathy, cardiomyopathy, osteoporosis, and peripheral neuropathy. Several randomized controlled trials report enhanced clinical outcomes when TCM formulations are used alone or in combination with conventional therapy.

TCM offers a promising complementary strategy for diabetes management and its associated complications. Further large-scale clinical trials are needed to validate efficacy and ensure safety.

## Linked entities

- **Diseases:** diabetes mellitus (MONDO:0005015), diabetic retinopathy (MONDO:0005266), cardiomyopathy (MONDO:0004994), osteoporosis (MONDO:0005298), peripheral neuropathy (MONDO:0003620)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** osteoporosis (MESH:D010024), metabolic disorder (MESH:D008659), Diabetes mellitus (MESH:D003920), cardiomyopathy (MESH:D009202), peripheral neuropathy (MESH:D010523), diabetic retinopathy (MESH:D003930), diabetes-related complications (MESH:D048909)
- **Chemicals:** glucose (MESH:D005947), Traditional (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12992034/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12992034/full.md

## References

170 references — full list in the complete paper: https://tomesphere.com/paper/PMC12992034/full.md

---
Source: https://tomesphere.com/paper/PMC12992034